Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Fiche publication
Date publication
octobre 2016
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LHERMITTE Benoît
Tous les auteurs :
Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME
Lien Pubmed
Résumé
EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter.
Mots clés
Adult, Aged, Brain Neoplasms, drug therapy, Chemoradiotherapy, methods, DNA Methylation, DNA Modification Methylases, genetics, DNA Repair Enzymes, genetics, Dacarbazine, administration & dosage, Female, Glioblastoma, drug therapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Promoter Regions, Genetic, genetics, Proportional Hazards Models, Sirolimus, administration & dosage, Tumor Suppressor Proteins, genetics, Young Adult
Référence
Clin. Cancer Res.. 2016 Oct 1;22(19):4797-4806